Asia Pacific Biologics Market Size & Outlook, 2026-2033
Global Market
Related Markets
Asia Pacific biologics market highlights
- The Asia Pacific biologics market generated a revenue of USD 139,914.4 million in 2025.
- The market is expected to grow at a CAGR of 10.4% from 2026 to 2033.
- In terms of segment, microbial was the largest revenue generating source in 2025.
- Microbial is the most lucrative source segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2026 to 2033.
Asia Pacific data book summary
| Market revenue in 2025 | USD 139,914.4 million |
| Market revenue in 2033 | USD 310,813.4 million |
| Growth rate | 10.4% (CAGR from 2026 to 2033) |
| Largest segment | Microbial |
| Fastest growing segment | Microbial |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Microbial, Mammalian |
| Key market players worldwide | Samsung BioLogics, Amgen Inc, Novo Nordisk A/S ADR, AbbVie Inc, Sanofi SA, Johnson & Johnson, Celltrion Healthcare, Bristol-Myers Squibb Co, Eli Lilly and Co, Roche Holding AG ADR |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 22.3% of the global biologics market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 310,813.4 million by 2033.
The Asian biologics industry is growing at a lucrative pace and is expected to emerge as the fastest-growing country owing to factors such as regulatory changes, improved infrastructure, and the presence of a large number of patients.
These regulatory changes are aimed at alignment with clinical research activity and accelerating drug approvals. Moreover, growth in the number of clinical studies conducted in the region has contributed in helping regulatory authorities with an improved understanding of the development of healthcare products.
Furthermore, the fact that conducting clinical trials in countries such as India is relatively less expensive compared to western countries has also contributed in the migration of several biologic developing companies towards this region.
No credit card required*
Publish Date: Jun 11, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Biologics Market Scope
Biologics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Johnson & Johnson | View profile | 134,400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | www.jnj.com |
| Amgen Inc | View profile | 26,700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | www.amgen.com |
| Roche Holding AG ADR | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| AbbVie Inc | View profile | 50,000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | www.abbvieinvestor.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| Eli Lilly and Co | View profile | 43,000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | www.lilly.com |
| Novo Nordisk A/S ADR | View profile | 66,015 | Novo Alle 1, Bagsvaerd, Denmark, 2880 | www.novonordisk.com |
| Samsung BioLogics | View profile | 1001-5000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | www.samsungbiologics.com/ |
| Celltrion Healthcare | View profile | 51-100 | Incheon, Inch'on-jikhalsi, South Korea, Asia | www.celltrionhealthcare.com/ |
Asia Pacific Biologics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Biologics Market Outlook will help companies and investors design strategic landscapes.
Microbial was the largest segment with a revenue share of 64.78% in 2025.
Horizon Databook has segmented the Asia Pacific biologics market based on microbial, mammalian covering the revenue growth of each sub-segment from 2021 to 2033.
The Asian biologics industry is growing at a lucrative pace and is expected to emerge as the fastest-growing country owing to factors such as regulatory changes, improved infrastructure, and the presence of a large number of patients.
These regulatory changes are aimed at alignment with clinical research activity and accelerating drug approvals. Moreover, growth in the number of clinical studies conducted in the region has contributed in helping regulatory authorities with an improved understanding of the development of healthcare products.
Furthermore, the fact that conducting clinical trials in countries such as India is relatively less expensive compared to western countries has also contributed in the migration of several biologic developing companies towards this region.
- Asia Pacific Biologics Market Source Outlook (Revenue, USD Million , 2021-2033)
- Microbial
- Mammalian
- Others
- Asia Pacific Biologics Market Product Outlook (Revenue, USD Million , 2021-2033)
- Monoclonal antibodies (MABs)
- Vaccines
- Recombinant Proteins
- Antisense & RNAi Therapeutics
- Others
- Asia Pacific Biologics Market Disease Category Outlook (Revenue, USD Million , 2021-2033)
- Oncology
- Infectious Diseases
- Immunological Disorders
- Cardiovascular Disorders
- Haematological Disorders
- Others
- Asia Pacific Biologics Market Manufacturing Outlook (Revenue, USD Million , 2021-2033)
- In-house
- Outsourced
Reasons to subscribe to Biologics Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Biologics Market Outlook databook
- Our clientele includes a mix of Biologics Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific Biologics Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific Biologics Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Asia Pacific Biologics Market, 2021-2033 (US$M)
Asia Pacific Source - Biologics Market Statistics, 2025 - 2033 (US$M)
Related industry reports
No Records
No related reports found.
Related statistics
No Records
No related statistics found.